A Phase 1 Study to Evaluate the Safety and Tolerability of a Study Drug in Subjects with Early Alzheimer's Disease (AD)
This study will test the safety and tolerability of an experimental study drug that may delay Alzheimer’s disease (AD) onset or slow the progression of possible AD-related damage due to protein build-up in the brain. Methods include measuring the amount of study drug and drug-related material in the cerebrospinal fluid (CSF, the fluid surrounding the brain and spinal cord) and blood, and measuring the effect of the study drug on the levels of certain proteins associated with AD in the blood and CSF.
The purpose of this study is to determine the safety and tolerability of multiple doses of Posiphen on subjects with early Alzheimer's Disease (AD) with up to 23-25 days of daily usage, and to implement a lumbar puncture (spinal tap) cerebrospinal fluid (CSF) study.
Participants will be paid for their participation.
- IRB Number: 1608086953
- Research Study Identifier: TX7396
- Principal Investigator: Martin Farlow, MD